Several new and emerging biotechnology companies gave presentations atthe Biopartnering Europe conference, held October 6-7 in London, UK. This is the first of a series of articles focusing on the new players.
Prolifix Ltd
Prolifix of the UK is an early-stage biotechnology company with the objective of discovering and developing novel drugs for proliferative diseases. Formed in September 1995 with L1.5 million ($2.4 million) in start-up financing (L1 million of which came from Chugai of Japan), Prolifix had another financing round earlier this year and raised L5.5 million, providing enough cash to last the firm for the next two and a half years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze